Date: 2013-01-04
Type of information: IPO
Company: Theradiag (France)
Investors: institutional investors
public
Amount: €8.6 million
Funding type: IPO
Planned used: This capital increase aims to give Theradiag the means to strengthen its expertise and expand to new treatments for inflammatory and autoimmune diseases, cancer and AIDS.
Others: Theradiag, the theranostics and in vitro diagnostics company focused on autoimmune diseases, has launched its IPO on Alternext.
* On January 4, 2013, Theradiag has announced that the company has raised € 8.6 million with the exercise of the over-allotment option by BIL Finance. 69.002 additional new actions have been issued. The exercise of this option brings the total number of shares of common stock sold in the IPO to 1.479.379 new additional shares. The total number of shares will be 3.824.699 shares.
* On December 6, 2012, Theradiag has announced that the total number of shares offered was oversubscribed nearly 2 times. Aggregate demand in the context of the IPO was on € 15.1 million. Consequently, the Company has chosen to set the issue price of new shares to € 5.80, corresponding to the top of the price range. In addition, given the success of the request, the Company decided to fully exercise the extension clause bringing the bid amount to € 8.2 million.The price of the retail offering and global offering is set at € 5.80 per share.This price represents a market capitalization of approximately Theradiag € 21.8 million.
Size of the offering and product gross proceeds (before over-allotment option)
• 1,410,377 new shares were issued in connection with the offering (including 183,962 under the extension clause), this number may be increased to a maximum of 1,621,933 new shares in case of full exercise of overallotment option.
• The gross proceeds of the issue after full exercise of the extension option is approximately € 8.2 million. This amount may be increased to a maximum of € 9.4 million in the event of full exercise of the overallotment option.
Given the success of the operation, investment funds managed by Truffle Capital finally subscribed 750,000 euros as part of their commitment.
The allocation of 1,410,377 new shares issued under the Offer is:
- Global Placement: 271,549 shares allocated to institutional investors;
- Open Offer Price: 1,138,828 shares allocated to the public.
The shares will be traded from 11 December 2012 on NYSE Alternext Paris under ISIN code FR0004197747 mnemonic and ALTER.
Therapeutic area: Diagnostic - Autoimmune diseases - Inflammatory diseases- Infectious diseases - Cancer -Oncology
